Filing Flows › CorMedix (CRMD) › Q2 2026 › vs Q1 2026
CorMedix (CRMD) Q2 2026 vs Q1 2026 (quarter over quarter)
CorMedix's revenue fell $25.5M (-20%) from $127M in Q1 2026 to $102M in Q2 2026. Gross margin 75.7% against 82.5% (-6.8 pts).
CorMedix, Q2 2026: revenue $102M (+156% year over year), operating margin 42.1%, net earnings $26.0M, operating cash flow $86.2M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 75.7% | 82.5% | -6.8 pts |
| Operating margin | 42.1% | 50.0% | -7.9 pts |
| Net margin | 25.5% | 30.3% | -4.8 pts |
| Free cash flow margin | 84.1% | 32.7% | +51.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $102M | $127M | −$25.5M | -20% |
| Gross profit | $77.1M | $105M | −$28.0M | -27% |
| Cost of revenue | $24.8M | $22.3M | $2.5M | +11% |
| Operating profit | $42.9M | $63.7M | −$20.7M | -33% |
| Operating expenses | $34.2M | $41.5M | −$7.2M | -17% |
| Pre-tax earnings | $38.7M | $55.6M | −$16.9M | -30% |
| Other expense, net | $4.2M | $8.0M | −$3.8M | -48% |
| Research & development | $6.7M | $7.2M | −$528K | -7% |
| Sales & marketing | $12.4M | $12.5M | −$85K | -0.7% |
| General & admin | $15.1M | $21.7M | −$6.6M | -31% |
| Net earnings | $26.0M | $38.6M | −$12.6M | -33% |
| Income tax | $12.7M | $17.0M | −$4.3M | -25% |
| Depreciation & amortization | $10.5M | $10.5M | −$4K | 0% |
| Share-based compensation | $4.1M | $4.6M | −$498K | -11% |
| Working capital & other | $45.6M | −$11.3M | $57.0M | — |
| Operating cash flow | $86.2M | $42.4M | $43.9M | +103% |
| Free cash flow (OCF − capex) | $85.7M | $41.7M | $44.0M | +106% |
| Capital expenditures | $561K | $729K | −$168K | -23% |
Questions
How much did CorMedix's revenue grow quarter over quarter in Q2 2026?
CorMedix's revenue fell $25.5M (-20%) from $127M in Q1 2026 to $102M in Q2 2026. Gross margin 75.7% against 82.5% (-6.8 pts).